Rare Infectious Disease News

Spotlight On

Anthrax

Anthrax is a serious infectious disease caused by gram-positive, rod-shaped bacteria known as Bacillus anthracis

Prevelance

Unknown

US Estimated

Unknown

Europe Estimated

Age of Onset

no.svg

ICD-10

N/A

Inheritance

Autosomal dominant

no.svg

Autosomal recessive

no.svg

Mitochondrial/Multigenic

no.svg

X-linked dominant

no.svg

X-linked recessive

no.svg

5 Facts you should know

FACT

1

Can occur in four forms: skin, lungs, intestinal, and injection.

FACT

2

Symptom onset occurs between one day to over two months after the infection is contracted.

FACT

3

Skin infections represent more than 95% of cases - without treatment, the risk of death from skin anthrax is 25%.

FACT

4

Does not typically spread directly between people.

FACT

5

Human anthrax is most common in Africa and central and southern Asia.

Anthrax is also know as...

Anthrax

Ragpicker's disease; Wool sorter's disease; Black Baine; Malignant edema; Malignant pustule; Siberian Plague

What’s your Rare IQ?

Which form of anthrax is considered to be the most deadly?

Common signs & symptoms

Current treatments

Raxibacumab

(Brand name: Abthrax) Manufactured by Human Genome Sciences, Inc.
FDA-approved indication: Treatment of inhalation anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs, and for prophylaxis of inhalation anthrax when alternative therapies are not available or are not appropriate.

obiltoxaximab

(Brand name: Anthim) Manufactured by Elusys Therapeutics, Inc.
FDA-approved indication: Treatment of adult and pediatric patients with inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs and for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate.

anthrax immune globulin (human)

(Brand name: Anthrasil) Manufactured by Emergent Biosolutions
FDA-approved indication: Treatment of inhalational anthrax in adult and pediatric patients in combination with appropriate antibacterial drugs

Top Clinical Trials

TitleDescriptionPhasesStatusInterventionsMore Information
A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Anthrax Vaccine in Healthy AdultsThe purpose of this clinical trial is to evaluate the safety and immunogenicity of BW-1010.
BW-1010 is a nanoemulsion adjuvanted recombinant protein (rPA) that would protect against fatal outcome resulting from exposure to anthrax.
Phase 1Active, not recruitingBiological: BW-1010: 50 µg - sprayer - IN|Biological: BW-1010: 50 µg - pipette - IN|Biological: BW-1010: 100 µg - sprayer - IN|Biological: BW-1010: 100 µg - pipette - IN|Biological: Saline (Placebo) - sprayer - IN|Biological: Saline (Placebo) - pipette - IN|Biological: BioThrax (positive control) - SCClick here for more information
Anthrax AV7909 Liquid vs LyophilizedThis is a randomized, parallel-group, double-blind, Phase 1 study designed to assess safety, tolerability and immunogenicity 2 formulations of adjuvanted anthrax vaccine (AV7909), lyophilized and liquid.Phase 1Not yet recruitingBiological: AV7909Click here for more information

Top Treatments in Research

AgentClass/Mechanism of ActionDevelopment StatusCompanyClinical StudiesMore Information
BW-1010BW-1010 combines BlueWillow’s patented technology, a novel oil-in-water emulsion platform that efficiently presents antigens to the immune system via the nasal mucosa, with Porton Biopharma Limited’s (PBL) recombinant protective antigen (rPA) for anthrax. Phase 1BlueWillow Biologics. Porton Biopharma Ltd.Click here for more informationClick here for more information
AV7909This is a randomized, parallel-group, double-blind, Phase 1 study designed to assess safety, tolerability and immunogenicity 2 formulations of adjuvanted anthrax vaccine (AV7909), lyophilized and liquid.Phase 1AV709 is being evaluated by National Institute of Allergy and Infectious Diseases (NIAID)
Click here for more informationClick here for more information